An official website of the United States government
Home
Name
HAD
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for HAD
Name
Alternate Names
ENT 50852
ENT-50852
Hemel
Hexalen
hexamethyl- (8CI)
Hexamethylenamine
Hexamethylmelamine
Hexastat
Melamine
NC 195
NCI-C50259
Abbreviations
HMM
HTM
HXM
Category
Chemotherapy
Subcategory
Cytotoxic antineoplastic
NSC Number
013875
13875
Primary Site
Ovarian cancer
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
14-hydroxy-daunomycin
Adri-blastina (Italy)
Adriamycin
Adriamycin-TM
Caelyx
FT-106
Hydroxydaunomycin
Myocet
Pegylated Liposomal Doxorubicin Hcl
Rubex
S-DOX
Stealth(R) Liposomal Doxorubicin
Abbreviations
ADM
ADR
ADRI
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
123127
Primary Site
Histology
None
Remarks
Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic
Coding
This drug should be coded
Name
Alternate Names
Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum
Abbreviations
CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP
Category
Chemotherapy
Subcategory
Alkylating agent
Platinum analog
NSC Number
119875
Primary Site
Histology
None
Remarks
An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.
Coding
This drug should be coded
